AstraZeneca and Amgen's Tezspire Achieves All Primary and Secondary Endpoints in Phase III CROSSING Trial for Eosinophilic Esophagitis

1 source ·1 article ·Aug 27, 06:01 UTC Astrazeneca Leishen Energy Holding Co., Ltd. Information Services

On 27 August 2026, AstraZeneca (LSE/STO/NYSE: AZN) announced that Tezspire (tezepelumab), co-developed with Amgen, delivered statistically significant and clinically meaningful improvements across both co-primary and all key secondary endpo…

Covered by 1 outlet

Kalkinemedia 1

All coverage · 1 article

Kalkine Media UK ·Aug 27, 06:01 UTC

AstraZeneca and Amgen's Tezspire Achieves All Primary and Secondary Endpoints in Phase III CROSSING Trial for Eosinophilic Esophagitis

AstraZeneca and Amgen's Tezspire Achieves All Primary and Secondary Endpoints in Phase III CROSSING Trial for Eosinophilic Esophagitis →

AstraZeneca and Amgen's Tezspire Achieves All Primary and Secondary Endpoints in Phase III CROSSING Trial for Eosinophilic Esophagitis